Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K R Herrlinger

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Gut|October 14, 2004
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expressionJ Wehkamp, J Harder, M Weichenthal, et al.
Journal of Crohn'S & Colitis|October 20, 2012
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE studyK R Herrlinger, M Diculescu, K Fellermann, et al.
Digestion|February 24, 2006
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working partyN K H de Boer, W Reinisch, A Teml, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Gut|October 14, 2004
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expressionJ Wehkamp, J Harder, M Weichenthal, et al.
Journal of Crohn'S & Colitis|October 20, 2012
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE studyK R Herrlinger, M Diculescu, K Fellermann, et al.
Digestion|February 24, 2006
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working partyN K H de Boer, W Reinisch, A Teml, et al.
Pageof 3